Reported time to AE onset1,2
AE management
Monitoring
For early identification and management of AEs, a series of follow-up appointments are recommended. Below is a table displaying the recommended follow-up schedule for patients receiving GIOTRIF® (afatinib) treatment:
aBy an oncologist or an oncology nurse on the basis of the hospital/centre organisation.
Adapted from Arriola E, et al. 2015.1
Typical time to onset
Diarrhoea typically has the earliest onset of all common AEs (2-3 days)1
AE management
Common AEs associated with GIOTRIF® (afatinib) treatment are generally well managed with supportive care,3-6 and many of the most common AEs can potentially be managed by dose modification, without compromising efficacy.7-9 For more information on how some of the most common AEs associated with GIOTRIF® (afatinib) use can managed, explore the pages below.
AE=Adverse Event
References
- 1
- Arriola E, et al. Future Oncol. 2015;11(2):267–277.
- 2
- Aw DC, et al. Asia-Pac J Clin Oncol 2018;14(1):23–31.
- 3
- Sequist LV, et al. J Clin Oncol. 2013;31(27):3327–3334.
- 4
- Wu YL, et al. Lancet Oncol 2014;15(2):213–222.
- 5
- Park K, et al. Lancet Oncol 2016;17(5):577–589.
- 6
- Soria JC, et al. Lancet Oncol 2015;16(8):897–890.
- 7
- Yang JC, et al. Ann Oncol 2016;27(11):2103–2110.
- 8
- Hirsh V, et al. First-line afatinib versus gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): patient-reported outcomes and impact of dose modifications on efficacy and adverse events. ASCO. 3–7 June 2016. Chicago, IL, USA. Poster: 369.
- 9
- Halmos B, et al. Lung Cancer 2019;127:103–111.
